Portfolio

SOPHiA GENETICS raises $77 million to accelerate the democratization of data-driven medicine

JAN 04, 2019

BY BALDERTON

SOPHiA GENETICS today announced the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing. Balderton joined the round, along with Idinvest Partners and Alychlo. SOPHiA GENETICS was founded in Switzerland and is now co-based in Lausanne and Boston. The company combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Today, its universal platform, SOPHiA AI, is utilized by more than 850 hospitals across 77 countries and has already supported the diagnosis of over 300,000 patients. The platform enables healthcare professionals to make sense of complex genomic and radiomic data through advanced analysis in order to better diagnose and treat patients, both for oncology and hereditary disorders. With the new funding round, SOPHiA GENETICS has now raised a total of $140 million. This latest investment will allow the company to further grow the global community of hospitals using its technology. In particular, SOPHiA GENETICS will continue adding talent to reinforce its rapidly expanding presence in the US. In the year since our first investment in September 2017,  SOPHiA has been used by 300,000 patients, and now works with more than 850 hospitals in 77 countries around the world. They have opened their second HQ in Boston, and have expanded the product to include radiomic data and tertiary analysis of genomic sequences.

Dr. Jurgi Camblong, CEO and Founder of SOPHiA GENETICS.

Sophia stands out as one of the most exciting companies in genomic software in the world today.

James Wise, Balderton

Read more about the fundraise on the SOPHiA GENETICS site.

Read James’ Medium post about why we’re so excited about the company’s progress.